glp-1 market size 2024 Agonists Weight Loss Drugs Report, 2025-2030 GLP-1 Receptor Agonist Market Size

This means: They underwent extensive clinical trials Dosing, purity, and manufacturing are strictly regulates Safety and efficacy were evaluated in thousands of patients The formulation is standardized and consistent FDA approval ensures that what you are receiving has been rigorously tested for both safety and predictable results

A surgeons ability to offer both surgical and non-surgical options is an important differentiator in 2026

pubmed.ncbi.nlm.nih.gov/36356111/ #3

United States Maintains Market Leadership with Commercial Insurance Coverage Demand for obesity GLP-1 treatment in the United States is expanding at a CAGR of 25.4%, driven by growing commercial insurance coverage and strong consumer awareness of available treatments